
China’s NMPA Approves Toripalimab in First-Line Melanoma
China’s National Medical Products Administration has approved toripalimab (Tuoyi) for the frontline treatment of patients with unresectable or metastatic melanoma.1 The approval was supported by data from the phase 3 MELATORCH study (NCT03430297). Data …